Abstract OBJECTIVES: Our goal was to analyse the haemodynamic and clinical results after implantation of the Freedom SOLO stentless aortic valve replacement by assessing the immediate postoperative results regarding mortality, discharge echocardiographic gradients and reoperation rates and by evaluating these results in the medium term.
INTRODUCTION
It is hypothesized that stentless valves mimic native flow and disrupt aortic root dynamics to a lesser extent than conventional stented xenograft valves [1, 2] . Because of the absence of a rigid sewing ring and their flexible design, they have a larger and non-obstructive effective orifice area with lower mechanical stress and decreased transvalvular gradients. Theoretically, these factors improve haemodynamic performance with an enhanced regression of left ventricular mass and possible improved survival, although articles in the literature are inconclusive regarding this issue [3, 4] . It is also thought that less turbulent flow could lead to improved durability. However, in practice, stentless valves have failed to live up to their potential. The complexity of implantation of the first-and second-generation stentless valves, associated with longer cross-clamp times and, therefore, higher morbidity, is a major reason for their limited usage [4] . Second, early degeneration of the Toronto SPV (St. Jude Medical, St. Paul, MN, USA), O'Brien (Cryolife Inc., Kennesaw, GA, USA) and Shelhigh valves (Shelhigh Inc., Millburn, NJ, USA) was surprisingly frequent [5] [6] [7] . Also, explantation of these valves is regarded as more challenging than that of conventional stented xenografts.
The Freedom SOLO valve (LivaNova PLC, London, UK) consists of 2 layers of bovine pericardium and was designed to tackle these problems. Implantation is simple and standardized with a single running suture line.
The durability of the valve should be enhanced due to the anticalcification treatment and the supra-annular, subcoronary positioning. The long-term durability of these valves has still to be evaluated; however, some centres report a high rate of early degeneration [8, 9] .
In this study, we assessed the clinical and haemodynamic performances of the Freedom Solo aortic valve, during the immediate postoperative period and during mid-term follow-up, by analysing our 9-year experience.
MATERIALS AND METHODS
This study was designed as a single-centre retrospective observational trial. Data were collected retrospectively from all patients undergoing an aortic valve replacement (AVR) with the Freedom Solo stentless valve.
Patient selection and data collection
Between May 2009 and May 2017, 625 patients underwent an AVR with the Freedom Solo stentless valve at Sint-Jan Hospital, Bruges. During this period, a total of 1246 AVRs were performed; 1058 of which were done with a bioprosthetic valve. The policy of our institution was to consider a Freedom Solo valve in all patients eligible for bioprosthetic AVR with no overt contraindications (bicuspid valve, extensive supra-annular calcification and sinotubular dilatation). Data were collected from the medical records and by contacting the referring centres. Demographic and preoperative data are presented in Table 1 . Postoperative transthoracic echocardiography was obtained before discharge and at various time intervals thereafter. Because the data for ventricular remodelling were incomplete due to the retrospective nature of the trial and the heterogeneous follow-up, they were not included in the trial.
Patients were censored by their last in-hospital contact or by contacting their general practitioner or referring centre. Three patients (0.5%) were lost to follow-up. The mean follow-up time was 2.8 ± 2.04 years (range 0-7.9 years), and the median followup period was 2.4 years. Cumulative follow-up included 1720 patient-years.
Definitions
Preoperative risk factors and morbidities were defined in accordance with the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) criteria.
Early mortality was defined as an all-cause mortality within the first 30 days after surgery, in accordance with the guidelines for reporting mortality and morbidity after cardiac valve interventions. Operated-valve endocarditis, reinterventions or other complications were reported according to these guidelines as well [10] . Structural valve deterioration (SVD) and non-structural dysfunction were determined by reoperation and analysis of the explanted valves. SVD was echocardiographically determined by the criteria defined by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery in 2017 [11] .
Surgical technique
All procedures were performed using the same implantation technique and by the same team of surgeons (M.S. W.R. and P.V.) at Sint-Jan Hospital, Bruges.
Isolated AVR was performed through a median sternotomy and with cardiopulmonary bypass. A transverse aortotomy was performed approximately 1.5-2 cm above the sinotubular junction after aortic cross-clamping and antegrade administration of cold cardioplegia solution (Custodiol V R ) via the root or selectively into both coronary arteries. After excision of the diseased native valve and after thorough decalcification, sizing was performed carefully to avoid oversizing. Three stay sutures were placed at the top of each commissure as a guide for sizing, suture placement and exposure. Using 3 polypropylene monofilament 4-0 sutures carefully positioned at the base of each sinus (the middle of the cusp) supra-annularly and through the valve, the valve was lowered into the supraannular position. No aortic enlargement procedures were needed. A running suture was performed in 6 parts, starting from the base and going to the top of the commissure as previously described [12] . The suture was brought out extra-aortically and tied on a pledget. The aorta was closed using a double-layer suture: first, a Blalock suture and second, a running suture.
Reasons not to implant a Solo valve were an asymmetric or bicuspid valve, extensive supra-annular aortic calcification, wide sinuses of Valsalva or a dilated ascending aorta. Intraoperative transoesophageal echocardiography was performed at the end of the procedure. Postoperatively, all patients received platelet antiaggregation therapy (acetylsalicylic acid).
Statistical analyses
Continuous data are shown as mean ± standard deviation or as median (Q1-Q3) according to the distribution of the data. Categorical variables are expressed as number and percentage. Echocardiographic gradients are graphically depicted as boxand-whisker plots to visualize variability and illustrate their progress over time.
Rates of overall survival were estimated according to the Kaplan-Meier method. Data on survival were administratively censored on 2 October 2017, except for data on 3 patients who were lost to follow-up.
Observations of our study population were matched to those of the Belgian population who were of the same gender and age in 2008 to calculate the expected survival probability during their respective follow-up time. Data were obtained from the Belgian Office for Statistics (https://statbel.fgov.be/nl).
Rates of reoperation (for SVD or endocarditis) were estimated according to the Kaplan-Meier method and the method of cumulative incidence, considering death and reoperation for other reasons as competing risks.
Statistical analyses were performed with SPSS (IBM SPSS Statistics for Windows, version 24, IBM Corp., Armonk, NY, USA) and the survival package (version 2.41-3) and the Subdistribution Analysis of Competing Risks package (version 2.2-7) in R version 3.4.1 (R Core Team, Vienna, Austria).
This study was approved by the local ethics committee, and patient consent was waived.
RESULTS
Baseline patient characteristics are presented in Table 1 . Our population had a mean age of 76 ± 6.9 years with a median EuroSCORE II of 2.75%.
Operative data and postoperative outcomes
All valve sizes were implanted during the study period; however, sizes 23 mm and 25 mm accounted for 74.9% of all implants. An 
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isolated AVR was performed in 239 patients (38.2%) with a mean cross-clamp time of 78.7 ± 28.59 min. The median stay in the intensive care unit of patients (all groups) was 5 days (Q1-Q3 3-7), and the median length of stay in the hospital was 13 days (Q1-Q3 10-16). Early reoperations occurred in 19 patients (3.0%), 10 of which were for bleeding and 8, for delayed tamponade One patient was reoperated on after triple-valve surgery with right heart failure and massive tricuspid regurgitation. A permanent pacemaker was implanted in 19 (3.0%) patients postoperatively. Twenty-two patients (3.5%) died in the first month postoperatively. Eleven patients died of non-cardiac causes (sepsis and respiratory problems); 8 died of cardiac causes; 2 died after a bleeding event and 1 died of sudden, unexplained causes. In the subgroup of patients who had an isolated AVR, 2 early deaths occurred (0.8%): 1 respiratory problems following pneumonia and 1 of sepsis.
Haemodynamic data
At discharge, all patients underwent an echocardiographic examination with peak gradients (Pmax) of 14.3 ± 8.14 and mean gradients (Pmean) of 7.5 ± 4.46. These gradients remained stable during the follow-up period as illustrated in Table 3 demonstrates gradually lower gradients with larger valve sizes.
Follow-up and explantations
During follow-up, 151 patients died: 84 of non-cardiac causes (55.6%), 25 of unknown causes (16.6%), 33 of cardiac causes (21.8%), 3 of valve-related causes (2.0%) and 6 of sudden unexplained causes (4.0%). Overall survival at 1, 5 and 7 years is 88% (95% CI 86-91), 70% (95% CI 65-75) and 55% (95% CI 47-62), respectively (Fig. 2) .
Fourteen patients underwent explantation of the bioprosthetic valve (Table 4) . Eight valves were explanted due to endocarditis and 2 because of SVD. Both these degenerated valves had a tear in the non-coronary cusp. There were no cases of stenotic or calcified degeneration during the study period. Other causes of explantation are explained in Table 4 .
At 7 years, freedom from reoperation overall, freedom from operation for endocarditis and freedom from operation for structural valve deterioration were 94% (95% CI 88-97), 97% (95% CI 94-99) and 98% (95% CI 90-99), respectively (Fig. 3) .
The cumulative incidence of reoperation for SVD, with death and other reoperations as a competing risk at 7 years, was 1.56% (95% CI 0-3.79%) (Fig. 4) .
DISCUSSION

Implantation-postoperative results
With an early mortality rate of 3.5% overall and of only 0.8% in cases with isolated AVR, our results compare well with those from the systematic review of Wollersheim et al. [13] that included 22 studies with SOLO implantations with an overall mortality rate of 3.5%. The mortality rate for isolated AVR in the Society of Thoracic Surgeons database of 141 905 patients was 3.0% [14] . Taking into consideration the high mean age of our patients (76 ± 6.9 years for the complete group and 76 ± 7.3 years for the isolated AVR group), we achieved a very low 30-day mortality rate. Cross-clamp time in isolated AVR was 78.7 ± 28.59 min, which is significantly higher than the mean of 66 min reported in the aforementioned review; however, this result is comparable to that obtained from the STS database, with a mean cross-clamp time of 77 min. In our institution, the cross-clamp times for both stented and stentless bioprostheses are similar. We attribute these slightly higher cross-clamp times to the need for extensive decalcification and a meticulous implantation technique.
The number of pacemaker implantations in our population was slightly higher than the numbers reported in the literature [13] [14] [15] ; however, these numbers were still low, because pacemaker implantation for stented AVR is approximately 3-7% [16, 17] . This result is possibly related to the supra-annular implantation technique, which avoids damage to the conduction system.
A transient thrombocytopenia was noted in the majority of our population (72%); however, no related bleeding or thromboembolic complications were seen in the postoperative phase, as have been described by many studies in the literature [9, 15, 18] . This result is illustrated by our low revision rate for bleeding. The cause of this quantitative but clinically irrelevant phenomenon has yet to be elucidated [19] . Stanger et al. [20] suggested that it is an in vivo, valve-specific feature, not attributable to preanalytical errors, but presumably a chemically induced platelet lysis. Thrombocytopenia has been described after transcatheter valve replacement as well, where it was a marker (but not a cause) for worse patient outcome [21] . In our study, the long-term mortality rate was higher than that reported previously, obviously due to the high mean age of our population. This observation is illustrated by the fact that 56% of the late deaths were non-cardiac in origin. An age-and sexmatched Belgian population shows a drop in survival identical to that of our specific patient population (Fig. 2) .
Postoperative transvalvular gradients at discharge were considerably lower compared to those reported for stented xenografts and similar to those of other studies using the Freedom Solo valve [18, 22] . Of course, this outcome is a major anticipated advantage of the Solo valve.
Explantations and structural valve degeneration
During our follow-up period, 14 patients were reoperated on, 2 of whom were reoperated on for SVD, yielding 7 years of freedom from explantation for SVD of 98% (95% CI 90-99) and a 7-year cumulative incidence of 1.6%. Because younger age is an independent risk factor for SVD [23] , we should interpret this low incidence of SVD with caution, given that our study population has a relatively high mean age.
The 2 patients with a degenerated valve presented with acute dyspnoea and severe aortic regurgitation. A torn cusp just at the edge of the right, non-coronary commissure was the cause. The reoperations were straightforward, and both patients are doing well.
Interestingly, our study is similar to the series of Stanger et al. [9] , who reported 4 cases with tears in the non-coronary cuspright coronary cusp. A possible explanation is the commonly larger and asymmetric non-coronary cusp-right coronary cusp sinus, which could cause more mechanical stress on this leaflet. All these tears were in large prostheses (> _25 mm), as in our series. We have not explanted any calcified or stenotic valves so far, which limits our experience with a (presumed) challenging explantation [24] . In the study of Stanger et al. [9] , degenerative stenosis became clinically significant on average later than torn SVD, at 7.5 years and 6 years, respectively. In 2017, Sponga et al. [8] reported early degenerative stenotic degeneration in 11 patients, seen during their 10-year experience in 109 patients.
Both these studies report early degeneration with actuarial freedom from SVD of 70% at 9 years [9] and of 60% at 10 years [8] . However, it should be noted that, in the study of Sponga et al., only 10 patients have completed the 10-year follow-up period. Other recently published series show more favourable durability. Wollersheim et al. [18] reported a 6-year freedom from SVD of 98% in a cohort of 350 patients. Repossini et al. [25] published the largest long-term follow-up in 2016 with a 10-year freedom from SVD and reoperation for SVD of 90.8% and 91.9%, respectively. This result is comparable to the roughly 10% SVD at 10 years of stented bioprostheses in the literature, albeit lower than the excellent long-term results with the Carpentier-Edwards Perimount valve [26, 27] . These long-term results may look somewhat disappointing because, theoretically, a longer durability was expected due to the anticalcification treatment and lower transvalvular gradients; however, most series are small, and longer follow-up is awaited. A recently published study analysing AVR registry data in the UK over 15 years shows a larger hazard for death or reintervention for the Mitroflow and Freedom valves (including earlier generations) compared to other currently available valves, warranting scrutiny concerning long-term durability [28] .
Possible reasons for these heterogeneous results have been proposed [8, 9, 25] . The single-suture technique and the slight asymmetry of most native aortic roots rarely ensure a symmetric implantation and may result in high mechanical stress on the leaflets and enhance degeneration.
Oversizing may play a role in SVD, because all reported leaflet ruptures occurred in larger valves [24, 29] . Caprili et al. [30] reported an early calcified SVD, ascribing this to an asymmetrical native root and clear oversizing. It should be stated that correct sizing and perfectly symmetrical implantation may play an important role in long-term durability.
For this reason, contraindications for implantation such as grossly asymmetrical commissures, a dilated sinotubular junction and a bicuspid native aortic valve should be strictly followed. We hypothesize that, as experience accumulates and implantation is more precise, durability will improve. Another reason for these divergent results may be methodological. All of these long-term studies are retrospective, and echocardiographic follow-up is often incomplete. Echocardiographic criteria for SVD are used differently, and a clear distinction between structural and non-structural failure should be made. This distinction may change in the future, given that the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery recently published guidelines concerning bioprosthetic valve dysfunction [11] .
Limitations
This study was conducted in a single centre, without a control group. However, we believe a single centre may confer an advantage in terms of consistent technical, operative and postoperative management. Due to the retrospective design in a regional centre, echocardiographic results were heterogeneous and difficult to obtain, which may have led to an underestimation of SVD.
However, reoperation for SVD is a valid, objective estimation when echocardiographic data are lacking, considering the referral liability of our regional care network. The follow-up time is limited to the medium term.
Summary
This study represents the largest single-centre experience of Freedom Solo valve implantations with favourable postoperative outcomes and low transvalvular gradients. In our cohort, we noted a low incidence of SVD, confirming good medium-term durability.
Long-term results are expected to be published soon, better defining the role of the Freedom Solo in the surgical armamentarium.
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